Pandemic 2009 H1N1 virus infection in children and adults: A cohort study at a single hospital throughout the epidemic

International Archives of Medicine

Jin-Han Kang¹  Ji-Chang Kim³  Sun Hee Park⁴  Myung-Sook Kim⁴  You-Sook Youn²  Kyung-Yil Lee²  Eun-Ji Go²  Jung-Woo Rhim² 

[1] Departments of Pediatrics, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea;Department of Pediatrics, The Catholic University of Korea, Daejeon St. Mary's Hospital, 520 Daeheung-dong, Jung-gu, Daejeon 301-723, Republic of Korea;Department of Radiology, The Catholic University of Korea, Daejeon St. Mary's Hospital, 520 Daeheung-dong, Jung-gu, Daejeon 301-723, Republic of Korea;Department of Internal Medicine, The Catholic University of Korea, Daejeon St. Mary's Hospital, 520 Daeheung-dong, Jung-gu, Daejeon 301-723, Republic of Korea

关键词: Adults;    Children;    Pneumonia;    Epidemiology;    H1N1 influenza virus;   

Others  :  804619
DOI  :  10.1186/1755-7682-5-13

 received in 2011-11-21, accepted in 2012-03-26,  发布年份 2012

【 摘 要 】

Background

In 2009, there was an influenza pandemic in South Korea. The aim of this study was to evaluate the epidemiological, clinical and laboratory characteristics of this infection in children and adults.

Methods

We evaluated the epidemiologic characteristics of patients infected with the 2009 H1N1 influenza A virus (4,463 patients, age range from 2 mo to 86 y), and the clinical and laboratory findings of 373 inpatients (80/217 children, ≤ 15 y, had pneumonia and 36/156 adults, > 16 y, had pneumonia) in a single hospital during the epidemic.

Results

The majority of infected patients (94%) were less than 40 y, and greater than 90% of cases occurred during a two-month period. The rates of admission and pneumonia were 8.4% (373/4,463) and 2.5% (116/4,463), respectively. The rates of admission and pneumonia, total duration of fever, the frequency of underlying diseases, and the values of C-reactive protein and erythrocyte sedimentation rate tended to increase as age increased; highest rates were found in the ≥ 65 y group. Pneumonia was founded more boys than girls in children, but more female than male in adults. The adult patients with pneumonia had higher leukocyte counts with lower lymphocyte differentials than the group without pneumonia, as shown in children group.

Conclusion

Our results suggest that the immunologic reaction to viral insults may be associated with age, sex and underlying diseases, and that unknown herd immunity may affect populations. The patients with underlying diseases, especially in older patients may have immunologic insufficiency that is associated with immunologic consumption by the underlying diseases.

【 授权许可】

   
2012 Rhim et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Cox NJ, Subbarao K: Global epidemiology of influenza: Past and present. Annu Rev Med 2000, 51:407-421.
• [2]Lagacé-Wiens PR, Rubinstein E, Gumel A: Influenza epidemiology: past, present, and future. Crit Care Med 2010, 38(Suppl):e1-9.
• [3]Ostovar GA, Rubin LG, Rajan S, Sood SK, Kohn N: Comparison of the clinical features of children hospitalized with pandemic 2009 A H1N1 and seasonal influenza. Clin Pediatr (Phila) 2011, 50:348-354.
• [4]Rothberg MB, Haessler SD: Complications of seasonal and pandemic influenza. Crit Care Med 2010, 38(Suppl):e91-97.
• [5]Neumann G, Noda T, Kawaoka Y: Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
• [6]Writing commitee of the WHO consultation on clinical aspect of pandemic (H1N1) 2009 influenza: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010, 362:1708-1719.
• [7]Donaldson LJ, Rutter PD, Ellis BM, Greaves FE, Mytton OT, Pebody RG, Yardley IE: Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009, 339:b5213.
• [8]Centers for Disease Control and Prevention: Update: influenza activity - United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine. MMWR Morb Mortal Wkly Rep 2010, 59:423-430.
• [9]Kim JH, Yoo HS, Lee JS, Lee EG, Park HK, Sung YH, Kim S, Kim HS, Shin SY, Lee JK: The spread of pandemic H1N1 2009 by age and region and comparison among monitoring tools. J Korean Med Sci 2010, 25:1109-1112.
• [10]Lee KY, Rhim JW, Kang JH: Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: A need for early immune-modulators for severe cases. Med Hypotheses 2011, 76:64-69.
• [11]La Gruta NL, Kedzierska K, Stambas J, Doherty P: A question of self-reservation: immunopathology in influenza virus infection. Immunol Cell Biology 2007, 85:85-92.
• [12]Meunier I, Pillet S, Simonsen JN, von Messling V: Influenza pathogenesis: lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. Crit Care Med 2010, 38(Suppl):e21-29.
• [13]Ogra PL, Welliver RC Sr: Effects of early environment on mucosal immunologic homeostasis, subsequent immune responses and disease outcome. Nestle Nutr Workshop Ser Pediatr Program 2008, 61:145-181.
• [14]Nagelkerken L: Age-related changes in immune reactivity: the influence of intrinsic defects and a changed composition of the CD4+ T cell compartment. Exp Clin Immunogenet 1992, 9:195-202.
• [15]Sansoni P, Vescovini R, Fagnoni F, Biasini C, Zanni F, Zanlari L, Telera A, Lucchini G, Passeri G, Monti D, Franceschi C, Passeri M: The immune system in extreme longevity. Exp Gerontol 2008, 43:61-65.
• [16]Rhim JW, Lee KY, Youn YS, Kang JH, Kim JC: Epidemiological and clinical characteristics of childhood pandemic 2009 H1N1 virus infection: an observational cohort study. BMC Infect Dis 2011, 11:225. BioMed Central Full Text
• [17]Bishop JF, Mumane MP, Owen R: Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med 2010, 361:2591-2594.
• [18]Torres JP, O'Ryan M, Herve B, Espinoza R, Acuna G, Manalich J, Chomali M: Impact of the novel influenza A (H1N1) during the 2009 autumn-winter season in a large hospital setting in Santiago, Chile. Clin Infect Dis 2010, 50:860-868.
• [19]Wichmann O, Stöcker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns T: Pandemic influenza A (H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 2010, 15(18):pii:19561.
• [20]Amato-Gauci A, Zucs P, Snacken R, Ciancio B, Lopez V, Broberg E, Penttinen P, Nicoll A, European Influenza Surveillance Network EISN: Surveillance trends of the 2009 influenza A(H1N1) pandemic in Europe. Euro Surveill 2011, 16(26):pii: 19903.
• [21]Falagas ME, Koletsi PK, Baskouta E, Rafailidis PI, Dimopoulos G, Karageorgopoulos DE: Pandemic A(H1N1) 2009 influenza: review of the Southern Hemisphere experience. Epidemiol Infect 2011, 139:27-40.
• [22]Centers for Disease Control and Prevention (CDC): Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009, 58:521-534.
• [23]Korea Centers for Disease Control and Prevention: Serologic cross-reactivity of serum samples from different age groups in Korea against a novel influenza A (H1N1) virus. Public Health Weekly Report (Korea) 2009, 2:744-745.
• [24]Dudareva S, Schweiger B, Thamm M, Höhle M, Stark K, Krause G, Buda S, Haas W: Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period. PLoS One 2011, 6:e21340.
• [25]Chen CJ, Lee PI, Chang SC, Huang YC, Chiu CH, Hsieh YC, Chang SC, Chang FY, Lee JJ, Su SC, Shen GH, Chuang YC, Chen YS, Liu JW, Lin TY: Seroprevalence and severity of 2009 pandemic influenza A H1N1 in Taiwan. PLoS One 2011, 6:e24440.
• [26]Shulman ST, Shulman DL, Sims RH: The tragic 1824 journey of the Hawaiian King and queen to London: history of measles in Hawaii. Pediatr Infect Dis J 2009, 28:728-733.
• [27]Shanks GD, Lee SE, Howard A, Brundage JF: Extreme mortality after first introduction of measles virus to the polynesian island of Rotuma, 1911. Am J Epidemol 2011, 173:1211-1222.
• [28]Panum PL: Observations made during the epidemic of measles on the Faeroes islands in the year 1846. New York, NY: American Publishing Association; 1940.
• [29]Lee NS, Kim HY, Chae MH, Kim EM, Park SY, Han SH, Kwon OG, Uh Y: The influence of vaccination on the clinical features of hemorrhagic fever with renal syndrome in the last 5 years. Korean J Med 2009, 76:459-466.
• [30]Akgün KM, Pisani M, Crothers K: The changing epidemiology of HIV-infected patients in the intensive care unit. J Intensive Care Med 2011, 26:151-164.
• [31]O'Riodan S, Barton M, Yau Y, Reed SE, Allen U, Tran D: Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza. CMJA 2009, 182:39-44.
• [32]Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw S, Choong K, Lamontagne F, Turgeon AF, Lapinsky S, Ahern SP, Smith O, Siddiqui F, Jouvet P, Khwaja K, McIntyre L, Menon K, Hutchison J, Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P, Canadian Critical Care Trials Group H1N1 Collaborative: Critically ill patients with 2009 influenza A (H1N1) infection in Canada. JAMA 2009, 302:1872-1879.
• [33]Lau EH, Hsiung CA, Cowling BJ, Chen CH, Ho LM, Tsang T, Chang CW, Donnelly CA, Leung GM: A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan. BMC Infect Dis 2010, 10:50. BioMed Central Full Text
• [34]Frank C, Werber D, Cramer JP, Askar M, Faber M, Heiden MA, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Stark K, Krause G, the HUS Investigation Team: Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany - preliminary report. N Engl J Med 2011, 365:1771-1780.
• [35]Kim HS, Kim JH, Shin SY, Kang YA, Lee HG, Kim JS, Lee JK, Cho B: Fatal cases of 2009 pandemic influenza A (H1N1) in Korea. J Korean Med Sci 2011, 26:22-27.
• [36]World Health Organization: WHO guidelines for pharmacological management of pandemic influenza A (H1N1) 2009 and other influenza viruses. Part II: review of evidence. [http:/ / www.who.int/ csr/ resources/ publications/ swineflu/ h1n1_guidelines_pharmaceutical_mngt _part2.pdf] webcite21-22. Revised February: 2010
• [37]Kil HR, Lee JH, Lee KY, Rhim JW, Youn YS, Kang JH: Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 influenza virus. Crit Care 2011, 15:413. BioMed Central Full Text
• [38]Annane D: Pro: The illegitimate crusade against corticosteroids for severe H1N1 pneumonia. Am J Respir Crit Care Med 2011, 183:1125-1126.
• [39]Matthay MA, Lia KD: Con: Corticosteroids are not indicated for treatment of acute lung injury from H1N1 viral pneumonia. Am Respir Crit Care Med 2011, 183:1127-1128.
• [40]Witkop CT, Duffy MR, Macias EA, Gibbons TF, Escobar JD, Burwell KN, Knight KK: Novel influenza A (H1N1) outbreak at the US Air Force Academy: epidemiology and viral shedding duration. Am J Prev Med 2010, 38:121-126.
• [41]Confalonieri M, D'Agaro P, Campello C: Corticosteroids do not cause harmful increase of viral load in severe H1N1 virus infection. Intensive Care Med 2010, 36:1780-1781.
• [42]Centers for Disease Control and Prevention (CDC): Bacterial co-infections in lung tissue specimens from fatal cases of, pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009, 2009(58):1071-1074.